7-Apr-2025
Alternative approach to Lyme disease vaccine development shows promise in pre-clinical models
Tufts UniversityPeer-Reviewed Publication
After decades of trial and error, a promising new target for Lyme disease vaccine is emerging—the Lyme bacterial protein CspZ, which the bacteria use to evade detection from the body’s immune system. CspZ first emerged as a candidate while scientists were looking for proteins that might be evolutionarily conserved across different Lyme bacteria strains and so generate a broad protective response. A new study from a group of international researchers shows that the modified CspZ triggers an immune response targeting the CspZ protein’s exposed “Achilles heel.”
- Journal
- Nature Communications
- Funder
- NIH/National Institute of Allergy and Infectious Diseases, NIH/National Institute of Allergy and Infectious Diseases, NIH/National Institute of Allergy and Infectious Diseases, NIH/National Institute of Allergy and Infectious Diseases, Congressionally Directed Medical Research Programs